| 42.2 0.44 (1.05%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 50.99 | 1-year : | 54.14 |
| Resists | First : | 43.65 | Second : | 46.35 |
| Pivot price | 41.38  |
|||
| Supports | First : | 39.29 | Second : | 32.68 |
| MAs | MA(5) : | 41.73  |
MA(20) : | 42.17 |
| MA(100) : | 41.04 |
MA(250) : | 37.09 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 47.2 |
D(3) : | 38.4 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 46.59 | Low : | 26.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XENE ] has closed below upper band by 19.7%. Bollinger Bands are 44% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.98 - 43.19 | 43.19 - 43.37 |
| Low: | 40.74 - 40.98 | 40.98 - 41.18 |
| Close: | 41.84 - 42.21 | 42.21 - 42.53 |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Mon, 26 Jan 2026
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Thu, 22 Jan 2026
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Mon, 19 Jan 2026
Campbell & CO Investment Adviser LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Fri, 16 Jan 2026
Ten new Xenon hires receive 42,300 stock options vesting over 4 years - Stock Titan
Fri, 09 Jan 2026
XENE: JP Morgan Raises Xenon Pharmaceuticals' Price Target | XEN - GuruFocus
Mon, 05 Jan 2026
Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 7.179e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 5,890 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.3818e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 543.7 % |
| Return on Equity (ttm) | -29.5 % |
| Qtrly Rev. Growth | 7.5e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -46.07 |
| EBITDA (p.s.) | -2.70622e+008 |
| Qtrly Earnings Growth | -3.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -252 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.92 |
| Price to Cash Flow | 5.69 |
| Dividend | 0 |
| Forward Dividend | 5.93e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|